ROBERT BRUCE MEYER
Dentist in Cary, NC
License number
Pennsylvania DS023523L
Category
Dentistry
Type
Dentist
Address
Address
2
Cary, NC 27513
Pennsylvania
Pennsylvania
Professional information
Dr. Robert B Meyer, Cary NC - DDS (Doctor of Dental Surgery)
Specialties:
Orthodontics
Address:
1815 Kildaire Farm Rd STE C, Cary 27518
(919) 852-0009 (Phone)
(919) 852-0009 (Phone)
Languages:
English
Robert B Meyer, Cary NC
Specialties:
Dentist
Address:
1815 Kildaire Farm Rd, Cary, NC 27518
Methods For Improving Therapeutic Effectiveness Of Agents For The Treatment Of Solid Tumors And Other Disorders
US Patent:
5788958, Aug 4, 1998
Filed:
Sep 6, 1996
Appl. No.:
8/709938
Inventors:
Mark W. Dewhirst - Chapel Hill NC
Robert E. Meyer - Cary NC
Joseph Bonaventura - Beaufort NC
Joseph DeAngelo - Hamtramck MI
Robert E. Meyer - Cary NC
Joseph Bonaventura - Beaufort NC
Joseph DeAngelo - Hamtramck MI
Assignee:
Duke University - Durham NC
Apex Bioscience, Inc. - Durham NC
North Carolina State University - Raleigh NC
Apex Bioscience, Inc. - Durham NC
North Carolina State University - Raleigh NC
International Classification:
A61K 3177, A61K 3816, A01N 3724, C07C20513
US Classification:
424 7838
Abstract:
The present invention is directed to the use of an inhibitor of NO activity, such as a nitric oxide scavenger or an NO synthase inhibitor, as an antitumor therapy to reduce tumor blood flow and oxygenation. The invention is also directed to administration of a nitric oxide scavenger or a nitric oxide synthase inhibitor to enhance the effectiveness of tumor therapy with hypoxic or acidic chemotherapeutic agents or hyperthermia. The invention is also directed to the administration of a nitric oxide synthase substrate to a subject previously administered a nitric oxide synthase inhibitor, in order to selectively inhibit tumor perfusion. In a specific example, administration of cell free hemoglobin, a nitric oxide scavenger, in conjunction with mitomycin C, a hypoxic cytotoxin, results in a significant delay in tumor growth of a human tumor xenograft in a mouse compared to mitomycin C alone. In another example, the administration of an inhibitor of nitric oxide synthase followed by the administration of a substrate of the enzyme causes a specific irreversible reduction of tumor blood flow, while normal blood flow is restored.
Methods For Improving Therapeutic Effectiveness Of Agents For The Treatment Of Solid Tumors And Other Disorders
US Patent:
5554638, Sep 10, 1996
Filed:
May 20, 1994
Appl. No.:
8/246882
Inventors:
Mark W. Dewhirst - Chapel Hill NC
Robert E. Meyer - Cary NC
Joseph Bonaventura - Beaufort NC
Joseph DeAngelo - Hamtramck MI
Robert E. Meyer - Cary NC
Joseph Bonaventura - Beaufort NC
Joseph DeAngelo - Hamtramck MI
Assignee:
Duke University - Durham NC
Apex Bioscience, Inc. - Durham NC
North Carolina State University - Raleigh NC
Apex Bioscience, Inc. - Durham NC
North Carolina State University - Raleigh NC
International Classification:
A61K 3122, A61K 31415
US Classification:
514398
Abstract:
The present invention is directed to the use of an inhibitor of NO activity, such as a nitric oxide scavenger or an NO synthase inhibitor, as an antitumor therapy to reduce tumor blood flow and oxygenation. The invention is also directed to administration of a nitric oxide scavenger or a nitric oxide synthase inhibitor to enhance the effectiveness of tumor therapy with hypoxic or acidic chemotherapeutic agents or hyperthermia. The invention is also directed to the administration of a nitric oxide synthase substrate to a subject previously administered a nitric oxide synthase inhibitor, in order to selectively inhibit tumor perfusion. In a specific example, administration of cell free hemoglobin, a nitric oxide scavenger, in conjunction with mitomycin C, a hypoxic cytotoxin, results in a significant delay in tumor growth of a human tumor xenograft in a mouse compared to mitomycin C alone. In another example, the administration of an inhibitor of nitric oxide synthase followed by the administration of a substrate of the enzyme causes a specific irreversible reduction of tumor blood flow, while normal blood flow is restored.
Methods For Improving Therapeutic Effectiveness Of Treatment Of Vascularization Disorders
US Patent:
6020308, Feb 1, 2000
Filed:
Jul 31, 1998
Appl. No.:
9/126930
Inventors:
Mark W. Dewhirst - Chapel Hill NC
Robert E. Meyer - Cary NC
Joseph Bonaventura - Beaufort NC
Joseph DeAngelo - Hamtramck MI
Robert E. Meyer - Cary NC
Joseph Bonaventura - Beaufort NC
Joseph DeAngelo - Hamtramck MI
Assignee:
Duke University - Durham NC
North Carolina State University - Raleigh NC
Apex Bioscience, Inc. - Durham NC
North Carolina State University - Raleigh NC
Apex Bioscience, Inc. - Durham NC
International Classification:
A61K 3816, A61K 3514
US Classification:
514 6
Abstract:
The present invention is directed to the use of an inhibitor of NO activity, such as a nitric oxide scavenger or an NO synthase inhibitor, as as an adjunct to treatment of inappropriate tissue vascularization disorders.
Methods For Improving Therapeutic Effectiveness Of Agents For The Treatment Of Solid Tumors And Other Disorders
US Patent:
5612310, Mar 18, 1997
Filed:
May 24, 1993
Appl. No.:
8/066756
Inventors:
Mark W. Dewhirst - Chapel Hill NC
Robert E. Meyer - Cary NC
Joseph Bonaventura - Beauford NC
Joseph DeAngelo - Hamtramck MI
Robert E. Meyer - Cary NC
Joseph Bonaventura - Beauford NC
Joseph DeAngelo - Hamtramck MI
Assignee:
Duke University - Durham NC
North Carolina State University - Raleigh NC
Apex Bioscience, Inc. - Durham NC
North Carolina State University - Raleigh NC
Apex Bioscience, Inc. - Durham NC
International Classification:
A61K 3816
US Classification:
514 6
Abstract:
The present invention is directed to administration of a nitric oxide scavenger or a nitric oxide synthase inhibitor to enhance the effectiveness of tumor therapy with hypoxic or acidic chemotherapeutic agents or hyperthermia. In a specific example, administration of cell free hemoglobin, a nitric oxide scavenger, in conjunction with mitomycin C, a hypoxic cytotoxin, results in a significant delay in tumor growth of a human tumor xenograft in a mouse compared to mitomycin C alone.